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Abstract 
Background: Hospitalization is usually recommended for imported malaria. The goal of the present study is to evalu-
ate the evolution in clinical pathways while measuring their impact on mortality.
Methods: This is a 14-year prospective observational study divided into three periods. We evaluated for adult 
(≥15 years) and paediatric (<15 years) case trends in severity, clinical pathways (hospitalization in medical ward (MW) 
or intensive care unit (ICU), ambulatory care) and mortality.
Results: In total, 21,386 imported malaria cases were included, 4269 of them were paediatrics (20 %). Rises in severe 
forms for adults [from 8 % in period 1–14 % in period 3 (p = 0.0001)] and paediatrics [from 12 to 18 % (p < 0.0001)] 
were found. For adults, MW admission rates decreased [−15 % (CI 95 % −17; −13)] while ambulatory care [+7 % (CI 
95 % 5–9)] and ICU admission rates [+4 % (CI 95 % 3–5)] increased. For paediatrics, increase in ICU admissions (+3 %) 
was shown. We did not observe any change in overall mortality during the study periods, whether among adults or 
children, regardless of care pathway.
Conclusions: The present study indicates a changing management of imported malaria in adults, with an increas-
ing trend for ambulatory care. The absence of change in mortality for adults indicates that ambulatory care can be 
proposed for adults presenting non-severe imported malaria.
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Background
Malaria is diagnosed in 19–29 % of symptomatic travel-
lers, mainly Plasmodium falciparum malaria [1, 2]. There 
are 1500 cases in the USA and 12,000 cases per year in 
Europe, of which 4000 are in France [3–8]. Paediatric 
cases represent 15–20  % of imported malaria cases [9]. 
Patient management and access to care is dependent on 
clinical or biological severity [10–12]. Most guidelines 
call for systematic hospitalization for imported falcipa-
rum malaria [12–15]. In 1999, French guidelines recom-
mended systematic short hospitalization for falciparum 
malaria [8], and in 2007 ambulatory care for non-severe 
forms of P. falciparum imported malaria in adults [16]. 
Hospitalization rates for imported malaria vary between 
30 and 72  % [3, 17, 18]. All guidelines recommend that 
severe falciparum malaria be managed in intensive care 
units (ICU) [8, 12–16]. However, ICU admission fre-
quency varies between 2.6 and 5  % for adults [17, 18] 
against 7.4 % for children [9, 19].
The hypothesis of this work was that revision of guide-
lines, the availability of new oral treatments and the evo-
lution of patients’ characteristics could have modified 
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clinical practices in malaria case management in recent 
years. The aim was to identify trends in the management 
of malaria cases in Ile-de-France between 2000 and 2013. 
Over the study period, hospitalization rates in general 
medical ward (MW), intensive care units (ICU) and the 
proportion of patients in ambulatory care were iden-
tified, as well as their impact on mortality according to 
care pathway.
Methods
Study design and data source
In this observational study, data was collected pro-
spectively by the French National Reference Centre for 
Malaria (CNR-M) in metropolitan France, a network of 
about 100 hospitals. For each confirmed malaria case 
(positive blood smear), physicians in the network’s hos-
pitals complete a standard case report form (CRF) with 
demographic, epidemiological, clinical, and parasitologi-
cal data.
Study population
The study population consisted of all malaria cases 
reported by hospitals of the CNR located in Ile-de-France 
(Paris area) in order to ensure a greater degree of homo-
geneity in terms of population, access to health care and 
case management. First, the population is more homo-
geneous in this region of 12 million inhabitants, with a 
high proportion of African migrants. Moreover, 45  % 
of the 44 hospitals are academic hospitals, 25  % have 
infectious disease units, and others are major hospi-
tals with expertise in the management of malaria cases. 
Finally, a large proportion of imported malaria cases are 
reported by the hospitals located in Ile-de-France (54 % 
of imported malaria cases in 2013, CNR database, data 
not published). Data were collected prospectively and in 
a consistent manner, regardless of severity or type of care 
pathway. Children under 15 years of age were considered 
as paediatric cases.
Study period
Cases reported between January 2000 and December 
2013 were included. The study period was divided into 
three periods: Period 1: 2000–2003, Period 2: 2004–2008 
and Period 3: 2009–2013. The first guidelines for the 
management of imported malaria cases were put for-
ward by the French Infectious Diseases Society in 1999 
[8]. These recommendations were revised in 2007 and 
published in 2008 [16]. Then, first and third study periods 
started in 2000 and 2009, respectively, i.e., 1 year after the 
publication of each recommendation. Since 2003, new 
therapeutic oral administration options have been used 
as first-line treatment for imported malaria. The second 
period started in 2004.
Ethics statement
Data collection and storage by the CNR-M was approved 
by the French National Commission for Data Protec-
tion and Liberties (CNIL). Anonymized data have been 
extracted from the CNR-M database. The Ethics Com-




Two different definitions were used to classify malaria 
cases as severe cases. First, the clinical classification of 
the CNR-M: physicians rated patients according to their 
clinical judgment including patients clinical evalua-
tion and social context as: (i) asymptomatic malaria; (ii) 
uncomplicated malaria without vomiting; (iii) uncom-
plicated malaria with vomiting; (iv) severe malaria; or, 
(v) evolving visceral malaria. Second, the French crite-
ria for severe falciparum malaria [16] that were adapted 
to imported malaria and its management in a European 
context. These criteria were used for the entire study 
period, even if the recommendations were published in 
2008 (see Additional file 1). Severity was defined by the 
presence of at least one severity criterion.
Type of care pathways
Patients were considered as admitted to the ICU or MW 
if they had spent at least 1 day in ICU or in MW. Length 
of stay (LOS) in the MW and ICU was recorded.
Mortality
All deaths attributable to malaria were reported to the 
CNR by hospital correspondents and in the same way 
for hospitalized and ambulatory patients. In France, 
all deaths and their causes are reported to the Centre 
d’épidémiologie sur les causes médicales de décès [20]. 
This entity informs the CNR of any certificate indicating 
malaria as the leading or contributing cause of death.
Statistical analysis
Data were aggregated by month for assessment of trends. 
Trends in the monthly number of cases, severe cases and 
in the different pathways (ambulatory care or hospitali-
zation in MW or ICU) were displayed using time series 
analysis and smoothed with a two-degree polynomial 
regression. The trend in the number of malaria cases over 
the study period was tested using a simple linear regres-
sion. To describe the study population, quantitative vari-
ables were described with mean and standard deviation, 
and qualitative variables with numbers of patients and 
percentages. Chi 2 or Fisher test and Student or Wilcoxon 
tests were used to compare qualitative and quantitative 
variables between the three study periods. Description 
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and tests were performed for adult and paediatric cases 
together and separately for main outcomes (number of 
cases, proportion of severe cases and ambulatory care 
or hospitalization rates) and separately for MW and ICU 
admissions. The significance threshold was 0.05. Missing 
data were not discarded. Statistical analyses were per-
formed using R 3.1.2 software.
Results
Between 2000 and 2013, 21,386 malaria cases were 
reported to the CNR (see details in Additional file  2; 
Additional file 3 presents a flow chart of the study pop-
ulation). The total number of cases decreased during 
the study period (see Additional file  4). The trend line 
for all cases decreased significantly by 99 cases per year 
(p  <  10−4). The decrease was significant both in adult 
cases (63 cases per year, p < 10−4) and in paediatric cases 
(33 cases per year, p < 10−5).
Table  1 presents the evolution of patients’ main char-
acteristics over the study period. Falciparum malaria 
caused 88  % of all cases over the study period and this 
proportion increased significantly from 87  % in Period 
1 to 90  % in Period 3. Paediatric cases accounted for 
20  % (4269/21,386) of all cases, and there was a signifi-
cant decrease during the study period (32  % in Period 
1 against 18 % in Period 3). There was also a significant 
increase in the proportion of patients aged over 50 years.
Additional file  5 indicates the use of new oral anti-
malarial drugs (atovaquone-proguanil, artemether-
lumefantrine, dihydroartemisinin-piperaquine) in first 
intention in adult cases as the first-choice treatment dur-
ing Periods 2 and 3, as they were not available during 
period 1.
Frequency of severe forms
According to clinical classification, 5 % (CI 95 % 4.7–5.3) 
of all cases (1031/21,386) were severe, and this propor-
tion rose significantly from 3  % in Period 1 to 9  % in 
Period 3 (p < 10−15). The increase was observed both in 
adults (from 3 to 9 %, p < 10−15) and in children (from 2 
to 7 %, p < 10−6) (Table 1). In accordance with French cri-
teria, 10 % (CI 95 % 9.8–10.6) of all cases (2172/21,386) 
were severe cases and this proportion increased sig-
nificantly, from 8  % in Period 1 to 14  % in Period 3 
(p  <  10−15). This increase was observed both in adults 
(from 7 to 13 %, p < 10−15) and in children (from 12 to 
18 %, p = 0.0001) (Table 1 and Additional file 6).
Frequency of clinical pathways
A total of 11,208 patients [59  % (CI 95  % 58.2–59.7)] 
out of the 19,012 with non-missing data for type of care 
were hospitalized. Over the study period, this proportion 
dropped significantly for adults, from 57 % in Period 1 to 
50 % in Period 3 (p < 10−10), but not for children (from 78 
to 76 %, p = 0.2) (Table 2).
A total of 7503 patients [47 % (CI 95 % 46.0–47.5)] were 
hospitalized in a MW. The proportion of hospitalization 
in MW decreased significantly over the study period, 
from 55  % in Period 1 to 39  % in Period 3 (p  <  10−15). 
Among adults, this proportion fell considerably, from 
48  % in Period 1 to 34  % in Period 3 (p  <  10−15) while 
the mean duration of stay remained globally unchanged 
(from 3.9  days in Period 1 to 4.2  days in Period 3, 
p  =  0.08). However, in paediatric cases this trend was 
not significant (decrease from 74 % in Period 1 to 67 % 
in Period 3, p =  0.06), nor was the change in the mean 
duration of stay (from 2.7 days in Period 1 to 2.6 days in 
Period 3, p = 0.08) (Table 2; Fig. 1).
A total of 742 patients [4.3 % (CI 95 % 4. 6–5.0)] were 
admitted to an ICU. The proportion of ICU hospitaliza-
tions rose significantly over the study period from 3 % in 
Period 1 to 7  % in Period 3 (p  <  10−15). Among adults, 
this proportion increased from 4 % in Period 1 to 8 % in 
Period 3 (p < 10−7). Conversely, the mean duration of stay 
in ICU fell from 5.7 days to 3.3 days (p < 10−4). In paedi-
atric cases, this increase in ICU hospitalization was also 
significant, rising from 1 % in Period 1 to 4 % in Period 3 
(p < 10−9), while the mean duration of stay in ICU did not 
change significantly (from 2.5 days in Period 1 to 4.6 days 
in Period 3, p = 0.1) (Table 2; Fig. 2).
The proportion of patients admitted to an ICU com-
pared to all admitted patients (ICU/ICU  +  MW) was 
calculated. As presented in Table 2, there is an increas-
ing proportion of ICU admission between Period 1 and 
Period 3 among adults [from seven in Period 1 to 19 in 
Period 3 (p < 10−15)] and children [from 1.2 to 6 (<10−8)].
Eighty-eight per cent of adults [1261/1427 (CI 95  % 
87–90)] and 89 % (CI 95 % 86–91) of children (504/567) 
with severe malaria according to French criteria were 
hospitalized, whereas this proportion rose to 98  % of 
adults (801/816) and 99 % of children (151/152) classified 
as severe malaria cases by physicians. Among hospital-
ized adults with severe malaria according to French cri-
teria, 49 % (452/920) were admitted to an ICU, but this 
proportion rose to 72 % (422/590) for those classified as 
severe cases by physicians. Among paediatric patients 
hospitalized, 15 % (54/372) of severe cases according to 
French criteria and 51 % (52/101) of severe cases accord-
ing to clinical classification were admitted to an ICU.
Mortality
Of the 21,386 reported cases, 57 died: 54 adults and three 
children [overall mortality: 0.27  % (CI 95  % 0.2–0.35); 
adults 0.32 % (CI 95 % 0.24–0.41) and paediatrics 0.07 % 
(CI 95  % 0.01–0.21)]. Adult and paediatric mortality 
rates, in ICU were 5.47 and 2.38 %, respectively, whereas 
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five adults died in MW (0.01  %) and no children. In 
ambulatory care, only one adult (0.01 %) and no children 
died. Table 3 presents the mortality trends according to 
study period and clinical pathways and main characteris-
tics of dead patients.
Discussion
The present study shows a rise in the proportion of 
severe forms of imported malaria among adults and chil-
dren, a decrease in hospitalization rate and an increase in 
ambulatory care among adults, while for both adults and 
children a rise in ICU admissions. Despite these changes 
in severity and proposed care pathways, any increase in 
mortality was found during the study period.
The frequency of severe forms of imported malaria, 
based on classification by a clinician and according to 
objective criteria [8, 16], can be determined. According to 
each of the two definitions of severity, our results indicate 
increased frequency in severe forms of the disease, both 
among adults (+6 % and +6 %) and children (+5 % and 
+6  %). A significant upward trend in the frequency of 
certain criteria for severity was identified: impaired con-
sciousness, haemodynamic failure, jaundice, increased 
bilirubin, severe anaemia, hyperlactataemia, renal failure, 
and parasitaemia >4 %, and a rise in the number of aged 
cases. All them are recognized as a severity criterion [11, 
12, 14–16, 21].
The present study found major changes in the manage-
ment of patients with imported malaria during the study 
period. For adults only, a progressive decrease in global 
hospitalization rates (−7 %) between Period 1 and Period 
3, indicating that re-orienting adult subjects from hos-
pitalization towards outpatient care took the form of a 
switch from MW hospitalizations (−15 %) towards ambu-
latory care (+7 %). The observed rise in ambulatory care 
for adults can be interpreted as the consequence of French 
guidelines which, as early as 1999 [8], suggested ambula-
tory care for patients exhibiting neither severity criteria 
nor particular difficulties that could impede outpatient 
follow-up care. These guidelines were strengthened in 
2007 to formally recommend ambulatory care for such 
patients [16]. However, the biggest effects were observed 
between Periods 1 and 2, starting in 2000. This suggests 
that the practice of reducing MW hospitalizations in 
favour of ambulatory care preceded the 2007 guidelines, 
which merely confirmed and reinforced pre-existing prac-
tices. The availability of new oral anti-malarial treatments 
could also have played a role. Not significant modification 
in care pathways for children was observed, either in hos-
pitalization or in ambulatory care. However, the availabil-
ity of oral anti-malarial treatments adapted to paediatric 
patients remains limited in France, and the 2007 guide-
lines excluded paediatric cases [16]. Recently, the WHO 
has recommended early home-based management with a 
community health worker for children in endemic zones, 
thus limiting hospitalization to cases meeting severity 
criteria [12]. This strategy has shown results in terms of 
reducing both child mortality and costs [22, 23].
Table 2 Clinical pathways for adult and paediatric cases during the study periods (Period 1: 2000–2003, Period 2: 2004–
2008, Period 3: 2009–2013)
a There were 2251 and 688 missing values for adult and paediatric cases, respectively
Period 1 Period 2 Period 3 p value Period 2 vs Period 1 Period 3 vs Period 1
n (%) n (%) n (%) Difference (CI 95 %) Difference (CI 95 %)
Adulta n = 5185 n = 5159 n = 4643
 Overall hospitalization 2971 (57) 2729 (53) 2335 (50) <10−10 −4 (−6; −2) −7 (−9; −5)
 Medicine ward 2230 (48) 1578 (38) 1318 (34) <10−15 −10 (−13; −9) −15 (−17; −13)
 MW length of stay (mean ± SD) (days) 3.9 (4.0) 4.1 (4.5) 4.2 (3.6) 0.08 0.2 (−0.4; 0.09) 0.3 (0.05; 0.5)
 ICU 174 (4) 181 (4) 303 (8) <10−7 0 (0; 1) 4 (3; 5)
 ICU length of stay (mean ± SD) (days) 5.7 (7.1) 5.3 (8.3) 3.3 (3.5) <10−4 −0.4 (−1.2; 2.0) −2.4 (−3.3; −1.4)
 Proportion of ICU/total admissions (%) 7.2 10.3 18.7 <10−15 3.1 (2.8; 3.4) 11.5 (11; 12)
 Ambulatory care 2214 (43) 2430 (47) 2308 (50) 4.4.10−11 4 (2; 6) 7 (5; 9)
Childrena n = 1891 n = 1189 n = 847
 Overall hospitalization 1481 (78) 988 (83) 641 (76) 0.20 5 (2; 8) −2 (−6; 1)
 Medicine ward 1185 (74) 676 (74) 477 (67) 0.06 0 (−3; 4) −7 (−11; −3)
 MW length of stay (mean ± SD) (days) 2.7 (2.0) 2.5 (1.9) 2.6 (2.0) 0.08 −0.2 (−0.4; −0.03) −0.1 (−0.3; 0.12)
 ICU 14 (1) 40 (4) 30 (4) <10−9 3 (2; 5) 3 (2; 5)
 ICU length of stay (mean ± SD) (days) 2.5 (1.5) 2.1 (1.6) 4.6 (7.9) 0.10 −0.4(−1.4; 0.5) 2.1 (−2.2; 6.4)
 Proportion of ICU/total admissions (%) 1.2 5.7 5.9 <10−8 4.5 (3.9; 5.2) 4.7 (4.0; 5.4)
 Ambulatory care 410 (22) 201 (17) 206 (24) 0.20 −5 (−8; −2) 2 (−1; 6)
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The present study also observed an increase in ICU 
admissions rates, both for adults (+4 %) and for children 
(+3 %). For adults, a decrease in global admissions and in 
MW admissions was associated with an increase in the 
proportion of ICU admissions. While fewer than one in 
ten patients had been admitted to an ICU during Period 
1, this figure rose to almost one in five patients in Period 
3. Similarly, it was noted an increase in ICU admissions 
for children, but to a lesser extent. The observed rise in 
severe forms could explain these increasing rates of ICU 
admission of imported malaria cases. Current guidelines 
recommend ICU admission for cases presenting at least 
one of the severity criteria [10–16, 24, 25]. However, 
these criteria are not clearly distinguished from those 
indicating hospitalization in a general MW.
The global mortality rate in our study was 0.27 %, that 
is, 0.32 and 0.007 % for adults and children, respectively, 
and therefore close to previously reported rates [3–6, 
26–28]. ICU mortality (5.47  %) was close to previously 
reported rates [17, 21, 27, 28]. We found that adult mor-
tality rates in MW and ambulatory care were 0.1 and 
0.01  %. No child died in MW or ambulatory care. The 
mortality rate for patients admitted to MW has not been 
well documented, while ambulatory care mortality has 
Fig. 1 Trends in the proportion of hospitalization in medical ward during the study period among malaria cases reported in Ile-de-France, 2000–
20,013, by month, according to age group. The number reported above the curve is the observed proportion for each period (Period 1: 2000–2003, 
Period 2: 2004–2008, Period 3: 2009–2013). The figure shows the proportion of patients with malaria cases hospitalized in the general Medical 
Ward, by month, among cases reported to the CNR between January 1st, 2000 and December 31, 2013 (black lines), smoothed with a 2° polynomial 
regression line (red lines), in adults (a) and pediatric cases (b). Dotted red lines represent limits between the three study periods. Proportions are 
specified for each period
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not previously been reported. These mortalities rates are 
very low, then ambulatory care can be proposed. Mor-
tality seems to be concentrated among patients admit-
ted directly to ICU, that is, those initially exhibiting the 
clearest criteria for severity in a clinician’s view. Yet the 
increased frequency in severe forms and modifications 
in care pathways, particularly a rise in adult ambulatory 
care, might have led to fear an increase in mortality rates 
during the course of the study. On the contrary, no sig-
nificant change was observed during the study periods in 
either global mortality or in mortality rates according to 
clinical pathway, whether among adults or children.
Conclusions
The results of the present study confirm that care path-
ways were modified during the course of the study 
period. For adults, this modification was characterized 
by a reduction in hospitalizations in general MW and by 
a rise in ambulatory care; and for adults and children, by 
an increase in the proportion of patients admitted to an 
ICU. Most international guidelines call for hospitalization 
of patients suffering from imported malaria. The present 
study results underline the importance of better defined 
criteria for hospitalization in an MW and ICU. The lack 
of any significant change in mortality indicates that man-
agement of imported malaria in Ile-de-France (the global 
Fig. 2 Trends in the proportion of hospitalization in intensive care units during the study period among malaria cases reported in Ile-de-France, 
2000–20,013, by month, according to age group. The number reported above the curve is the observed proportion for each period (Period 1: 
2000–2003, Period 2: 2004–2008, Period 3: 2009–2013). The figure shows the proportion of patients with malaria cases hospitalized in ICU, by 
month, among cases reported to the CNR between January 1st, 2000 and December 31, 2013 (black lines), smoothed with a 2° polynomial regres-
sion line (red lines), in adults (a) and pediatric cases (b). Dotted red lines represent limits between the three study periods. Proportions are specified 
for each period
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strategy of reducing hospitalizations in MW and develop-
ing ambulatory care pathways for adults with non-severe 
forms), was not associated with a rise in mortality. Then, 
ambulatory care can be proposed for adults with non-
severe imported malaria. The present study provides an 
answer to an old question concerning the hospitalization 
of imported malaria [29, 30] and opens up new clinical 
possibilities and research perspectives in this field.
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a For five dead adults, the type of pathway was missing. Among hospitalized adults, the type of hospitalization was missing for seven adults
b The third dead child was hospitalized but the type of hospitalization was missing
Period 1 Period 2 Period 3 p value Period 2 vs Period 1 Period 3 vs Period 1
n (%) n (%) n (%) Difference (CI 95 %)) Difference (CI 95 %)
Adultsa n = 6482 n = 5514 n = 4989
 Overall mortality 24 (0.37) 16 (0.29) 14 (0.28) 0.35 −0.08 % (−0.3; 0.13) −0.09 % (−0.32; 0.12)
 P. falciparum 22 (0.34) 16 (0.29) 14 (0.28) 0.50
 Severity–French criteria 19 (0.29) 11 (0.2) 14 (0.28) 0.50
 Severity–clinical classification 21 (0.32) 15 (0.27) 14 (0.28) 0.50
 Medicine ward 2 (0.09) 1 (0.06) 2 (0.15) 0.87
 ICU 14 (8.5) 10 (5.52) 12 (3.96) 0.09
 Ambulatory care 1 (0.05) 0 (0) 0 (0) 0.13
Childrenb n = 2066 n = 1308 n = 895
 Overall mortality 2 (0.1) 0 (0) 1 (0.11) 0.52 −0.1 % (−0.47; 0.1) (0.01 % (−0.5; 0.29)
 P. falciparum 2 (0.1) 0 (0) 0 (0) 0.33
 Severity–French criteria 0 (0) 0 (0) 1 (0.11) 0.33
 Severity–clinical classification 1 (0.5) 0 (0) 1 (1.1) 0.33
 Medicine ward 0 (0) 0 (0) 0 (0)
 ICU 2 (14.9) 0 (0) 0 (0) 0.006
 Ambulatory care 0 (0) 0 (0) 0 (0)
Page 10 of 10Casalino et al. Malar J  (2016) 15:312 
Ghania Belkadi. Hôpital Saint Antoine-France (ghania.belkadi@aphp.fr)
Stephane Bretagne. Hôpital Saint Louis-France (stephane.bretagne@aphp.fr)
Guillaume Leloup-Hôpital Tenon-France (guillaume.leloup@aphp.fr)
Helene Lapillonne. Hôpital Trosseau-France (helene.lapillonne@aphp.fr)
Michel Thibault. Hôpital de Pontoise-France (michel.thibault@ch-pontoise.fr)
Nadine Godineau. Hôpital Delafontaine-France (nadine.godineau@ch-stdenis.
fr)
Odile Eloy. Hôpital de Versailles-France (odile.eloy@ch-versailles.fr)
Anne Goepp. Hôpital deVilleneuve-Saint Georges-France (anne.goep@chiv.fr)
Author details
1 Service d’Accueil des Urgences, Assistance Publique-Hôpitaux de Paris (AP-
HP), Hôpital Bichat-Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France. 
2 Université Paris Diderot, PRES Sorbonne Paris Cité, EA 7334 «Recherche 
clinique coordonnée ville-hôpital, Méthodologies et Société (REMES)», Paris, 
France. 3 INSERM, IAME, UMR 1137, 75018 Paris, France. 4 Service de Biostatis-
tique, AP-HP, Hôpital Bichat, 75018 Paris, France. 5 Université Paris Diderot, 
Sorbonne Paris Cité, 75018 Paris, France. 6 Parasitology Laboratory, Centre 
National de Référence du Paludisme, Assistance Publique-Hôpitaux de Paris 
(AP-HP), University Hospital Bichat-Claude Bernard, Paris, France. 7 RD UMR216, 
Mère et enfant face aux infections tropicales, 75006 Paris, France. 8 Faculté des 
Sciences Pharmaceutiques et Biologiques, PRES Sorbonne Paris Cité, Université 
Paris Descartes, 75270 Paris, France. 9 Centre National de Référence du Palud-
isme, Hôpital Bichat, 46 rue Henri Huchard, 75018 Paris, France. 
Acknowledgements
We are indebted with the CNR members. The CNR is funded by the French 
Ministry of Health. The authors did not receive any specific funding for this 
analysis.
Competing interests
The authors declare that they have no competing interests.
Received: 19 February 2016   Accepted: 27 May 2016
References
 1. Leder K, Torresi J, Libman MD, Cramer JP, Castelli F, Schlagenhauf P, et al. 
GeoSentinel surveillance of illness in returned travelers, 2007–2011. Ann 
Intern Med. 2013;158:456–68.
 2. Harvey K, Esposito DH, Han P, Kozarsky P, Freedman DO, Plier DA, et al. 
Surveillance for travel-related disease—GeoSentinel Surveillance System, 
United States, 1997–2011. MMWR Surveill Summ. 2013;62:1–23.
 3. Mali S, Kachur SP, Arguin PM. Malaria surveillance-United States, 2010. 
MMWR Surveill Summ. 2012;61:1–17.
 4. Cullen KA, Arguin PM. Malaria surveillance-United States, 2011. MMWR 
Surveill Summ. 2013;62:1–17.
 5. Public Health England. Imported malaria cases and deaths, United King-
dom: 1994–2013. Data from the PHE Malaria Reference Laboratory 2014. 
2015. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_
C/1195733773780#malgraph. Accessed 5 May 2016.
 6. Smith AD, Bradley DJ, Smith V, Blaze M, Behrens RH, Chiodini PL, et al. 
Imported malaria and high risk groups: observational study using UK 
surveillance data 1987–2006. BMJ. 2008;337:a120.
 7. Seringe E, Thellier M, Fontanet A, Legros F, Bouchaud O, Ancelle T, et al. 
Severe imported Plasmodium falciparum malaria, France, 1996–2003. 
Emerg Infect Dis. 2011;17:807–13.
 8. Société de Pathologie Infectieuse de Langue Française. Conférence de 
Consensus. Prise en charge et prévention du paludisme d’importation 
à Plasmodium falciparum. 1999. http://www.infectiologie.com/site/
medias/_documents/consensus/palu99.pdf. Accessed 15 Dec 2015.
 9. Ladhani S, Aibara RJ, Riordan FA, Shingadia D. Imported malaria in chil-
dren: a review of clinical studies. Lancet Infect Dis. 2007;7:349–57.
 10. World Health Organization Division of Control of Tropical Diseases. Severe 
and complicated malaria. Trans R Soc Trop Med Hyg. 1990;84(suppl 
2):1–65.
 11. World Health Organization Communicable Diseases Cluster. Severe 
falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94(suppl 1):S1–90.
 12. World Health Organization. Management of severe malaria. 3rd ed. 2012. 
http://apps.who.int/iris/bitstream/10665/79317/1/9789241548526_eng.
pdf. Accessed 5 May 2016.
 13. Whitty CJ, Chiodini PL, Lalloo DG. Investigation and treatment of 
imported malaria in non-endemic countries. BMJ. 2013;346:f2900.
 14. Muñoz J, Rojo-Marcos G, Ramírez-Olivencia G, Salas-Coronas J, Treviño B, 
Perez Arellano JL, et al. Diagnosis and treatment of imported malaria in 
Spain: recommendations from the Malaria Working Group of the Spanish 
Society of Tropical Medicine and International Health (SEMTSI). Enferm 
Infecc Microbiol Clin. 2015;33:e1–13.
 15. Singh K, Wester WC, Trenholme GM. Problems in the therapy for imported 
malaria in the United States. Arch Intern Med. 2003;163:2027–30.
 16. Société de Pathologie Infectieuse de Langue Française. Prise en charge et 
prévention du paludisme d’importation à Plasmodium falciparum; recom-
mandations pour la pratique clinique 2007. Révision de la conférence 
de consensus. 1999. http://www.infectiologie.com/site/medias/_docu-
ments/consensus/2007-paludisme-long.pdf. Accessed 5 May 2016.
 17. Bruneel F, Tubach F, Corne P, Megarbane B, Mira JP, Peytel E, et al. Severe 
imported falciparum malaria: a cohort study in 400 critically Ill adults. 
PLoS One. 2010;5:e13236.
 18. Marks ME, Armstrong M, Suvari MM, Batson S, Whitty CJ, Chiodini PL, et al. 
Severe imported falciparum malaria among adults requiring intensive 
care: a retrospective study at the hospital for tropical diseases, London. 
BMC Infect Dis. 2013;3:118.
 19. Driessen GJ, Pereira RR, Brabin BJ, Hartwig NG. Imported malaria in chil-
dren: a national surveillance in the Netherlands and a review of European 
studies. Eur J Public Health. 2008;18:184–8.
 20. Centre d’épidémiologie sur les causes médicales de décès (CépiDc) 
http://www.cepidc.inserm.fr/site4/. Accessed 5 May 2016.
 21. Dondorp MA, Lee SJ, Faiz M, Mishra S, Price R, Tjitra E, et al. The relation-
ship between age and the manifestations of and mortality associated 
with severe malaria. Clin Infect Dis. 2008;47:151–7.
 22. Comfort AB, van Dijk JH, Mharakurwa S, Stillman K, Gabert R, Korde S, 
et al. Hospitalizations and costs incurred at the facility level after scale-up 
of malaria control: pre-post comparisons from two hospitals in Zambia. 
Am J Trop Med Hyg. 2014;90:20–32.
 23. Chanda P, Hamainza B, Moonga HB, Chalwe V, Banda P, Pagnoni F. Relative 
costs and effectiveness of treating uncomplicated malaria in two rural 
districts in Zambia: implications for nationwide scale-up of home-based 
management. Malar J. 2011;10:159.
 24. WHO. International travel and health. Malaria. 2012. http://www.who.int/
ith/ITH_chapter_7.pdf?ua=1. Accessed 19 Dec 2015.
 25. Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, 
et al. UK malaria treatment guidelines. J Infect. 2007;54:111–21.
 26. European Centre for Disease Prevention and Control. 2013. Malaria. 
http://www.ecdc.europa.eu/en/healthtopics/malaria/Pages/public-
health-developments.aspx. Accessed 5 May 2016.
 27. Legros F, Bouchaud O, Ancelle T, Arnaud A, Cojean S, Le Bras J, et al. 
Risk factors for imported fatal Plasmodium falciparum malaria, France, 
1996–2003. Emerg Infect Dis. 2007;13:883–8.
 28. Lüthi B, Schlagenhauf P. Risk factors associated with malaria deaths in 
travellers: a literature review. Travel Med Infect Dis. 2015;13:48–60.
 29. Whitty CJ, Lockwood DN. Should patients with imported malaria rou-
tinely be admitted? BMJ. 2002;324:875.
 30. D’Acremont V, Landry P, Darioli R, Stuerchler D, Pécoud A, Genton B. Treat-
ment of imported malaria in an ambulatory setting: prospective study. 
BMJ. 2002;324:875–7.
